Urinary catecholamine and metanephrine to creatinine ratios in dogs with hyperadrenocorticism or pheochromocytoma, and in healthy dogs by Quante, Saskia
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2010
Urinary catecholamine and metanephrine to creatinine ratios in dogs with
hyperadrenocorticism or pheochromocytoma, and in healthy dogs
Quante, Saskia
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-163985
Dissertation
Published Version
Originally published at:
Quante, Saskia. Urinary catecholamine and metanephrine to creatinine ratios in dogs with hyperadreno-
corticism or pheochromocytoma, and in healthy dogs. 2010, University of Zurich, Vetsuisse Faculty.
Urinary Catecholamine and Metanephrine to Creatinine Ratios in
Dogs with Hyperadrenocort ic ism or Pheochromocytoma, and in
Healthy Dogs
S. Quante, F.S. Boretti, P.H. Kook, C. Mueller, S. Schellenberg, E. Zini, N.
Sieber-Ruckstuhl, and C.E. Reusch
Background: Urinary catecholamines andmetanephrines are used for the diagnosis of pheochromocytoma (PHEO) in dogs.
Hyperadrenocorticism (HAC) is an important differential diagnosis for PHEO.
Objectives: To measure urinary catecholamines and metanephrines in dogs with HAC.
Animals: Fourteen dogs with HAC, 7 dogs with PHEO, and 10 healthy dogs.
Methods: Prospective clinical trial. Urine was collected during initial work-up in the hospital; in dogs with HAC an addi-
tional sample was taken at home 1 week after discharge. Parameters were measured using high-pressure liquid chromatography
and expressed as ratios to urinary creatinine concentration.
Results: Dogs with HAC had signiﬁcantly higher urinary epinephrine, norepinephrine and normetanephrine to creatinine
ratios than healthy dogs. Urinary epinephrine, norepinephrine, and metanephrine to creatinine ratios did not differ between
dogs with HAC and dogs with PHEO, whereas the urinary normetanephrine to creatinine ratio was signiﬁcantly higher (P 5
.011) in dogs with PHEO (414, 157.0–925.0, median, range versus (117.5, 53.0–323.0). Using a cut-off ratio of 4 times the
highest normetanephrine to creatinine ratio measured in controls, there was no overlap between dogs with HAC and dogs with
PHEO. The variables determined in urine samples collected at home did not differ from those collected in the hospital.
Conclusion and Clinical Importance: Dogs with HAC might have increased concentrations of urinary catecholamines and
normetanephrine. A high concentration of urinary normetanephrine (4 times normal), is highly suggestive of PHEO.
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Pheochromocytomas (PHEOs) are catecholamine-producing neuroendocrine tumors arising from
chromafﬁn cells of the sympathoadrenal system. Clinical
signs usually result from secretion of excessive amounts
of catecholamines and include among others weakness,
episodic collapse, tachypnea, panting, tachycardia, pac-
ing, polyuria/polydipsia, hypertension-associated bleed-
ing, vomiting, and diarrhea. Occasionally, signs are
attributable to the space-occupying or invasive nature of
the tumor. Hormone secretion is sporadic and unpredict-
able, and the clinical presentation varies greatly with
signs similar to many other clinical conditions.1–3
Diagnosis of PHEO in humans is based mainly on
biochemical detection of excessive production of the
secretory products of the tumor. Widely used tests
include measurement of the concentration of catechola-
mines and their metabolites metanephrine and nor-
metanephrine in 24-hour urine samples, or metanephrines
in plasma.4 Although these tests are regarded as being
reasonably sensitive and speciﬁc, the diagnosis of PHEO
in human medicine remains challenging. Dogs with
PHEO might have only mild or inconsistent increases in
plasma or urine catecholamines/metanephrines and vari-
ous diseases and medications can increase catecholamine
synthesis and lead to false-positive results.5–7
Evaluation of diagnostic tests for PHEO in veterinary
medicine has only recently been carried out.8 Dogs with
PHEO had signiﬁcantly higher urinary epinephrine, nor-
epinephrine, and normetanephrine to creatinine ratios
compared with healthy dogs.9Whether other diseases cause
an increase in the concentration of urine catecholamines
and metanephrines has not been investigated in dogs.
Hyperadrenocorticism (HAC) is 1 of the most impor-
tant differential diagnoses for PHEO. Both diseases might
have similar clinical signs such as weakness, tachypnea,
panting, polydipsia/polyuria, hypertension-associated
bleeding as well as similar abnormalities of the adrenal
glands detected via ultrasonography. Additionally, it is
known from humans that glucocorticoids might increase
catecholamine production and release.10 The objective of
the study was to determine and compare the concentra-
tions of urine catecholamines and metanephrines in
healthy dogs, dogs with HAC and dogs with PHEO.
Materials and Methods
Animals and Criteria for Selection of Cases
Dogs with HAC. Dogs suspected of having HAC under-
went a thorough clinical examination, and blood and urine
samples were collected for a CBC, biochemical proﬁle, urinal-
ysis, and urine culture. Work-up included a low-dose
dexamethasone suppression (LDDS) test and measurement
of the urine cortisol to creatinine ratio (UCC) in urine samples
collected at home. In addition, the adrenal glands were exam-
ined ultrasonographically. All 14 dogs had a positive LDDS
test (cortisol 8 hours after 0.01mg/kg dexamethasone
41.0 mg/dL). In 12 dogs UCC was measured in 2 urine sam-
ples collected on consecutive days at home and was positive
(410106) in 10 dogs, in 2 dogs UCC was within the
reference range. In 1 dog UCC was measured once and was
found to be elevated. The following criteria were used for
inclusion of dogs in the study: the presence of clinical
signs consistent with HAC (polyuria, polydipsia [pu/pd],
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polyphagia, dermatological problems, decreased activity,
panting, pendulous abdomen); a minimum of 1 positive
screening test; agreement of the owner to regular re-evalua-
tions over a 6-month period; and other treatments for HAC
(eg mitotane, radiation) had not been instituted.
Pituitary-dependent HAC (PDH) was diagnosed by means
of a bilateral symmetrical appearance or bilateral enlargement
of the adrenal glands on ultrasonograms. All dogs with PDH
underwent therapy with trilostane starting with dosages of
2–5mg/kg, re-evaluations were performed as reported previ-
ously.11 To reduce the risk that concurrent PHEO was
present, only those dogs with well-controlled HAC and no
other clinical signs during a minimum of 6 months after start-
ing therapy were used in the study. Ten dogs with PDH,
ranging in age from 5 to 13 years (median 9) and weighing
8.2–58.0 kg (median 18.7), were used. Six dogs were male (4
castrated) and 4 were female (3 spayed). Breeds included Hov-
award (1), Dachshund (1), Petit Griffon Bleu (1), Tibetan
Terrier (1), Giant Schnauzer (1), and ﬁve mixed-breed dogs.
HAC caused by adrenocortical tumor (ATH) was diagnosed
when a mass was seen via ultrasonography in 1 or both adrenal
glands. ATH was conﬁrmed by histological examination of the
adrenal gland(s) after adrenalectomy and resolution of clinical
signs in 3 dogs; in another dog, the diagnosis was conﬁrmed by
postmortem examination. The 4 dogs with ATH (2 unilateral
adenoma, 1 bilateral adenoma, 1 carcinoma) were 9, 9.3, 10,
and 12 years old and weighed 5, 10, and 32 (2)kg, respectively.
Two of them were male, 2 were female (1 spayed), and breeds
included Miniature Poodle, West Highland White Terrier, Ital-
ian Cattle Dog, and Golden Retriever.
Dogs with PHEO. Seven dogs with PHEO were included;
the results of 6 were part of a previous study.9 Dogs had var-
ious clinical signs including weakness, polyuria/polydipsia,
tachypnea, tachyarrhythmia, or collapse. Ultrasonography
identiﬁed unilateral adrenal masses in 6 dogs (left adrenal
gland in 4 dogs, right adrenal gland in 2 dogs) and bilateral
masses in 1 dog. Diagnosis of PHEO was conﬁrmed by histo-
logical examination of the adrenal gland(s) after
adrenalectomy or postmortem examination. The dogs were
11–16 years old (median 12) and weighed 2.8–41.8 kg (median
20). Four of them were male (2 castrated) and 3 were spayed
females, and breeds included Yorkshire Terrier (1), Cairn
Terrier (1), Bearded Collie (1), Boxer (1), Bernese Mountain
Dog (1), and 2 mixed-breed dogs.
Healthy Dogs. Ten healthy client-owned dogs were in-
cluded as controls.9 The dogs were considered healthy based
on information provided by their owners, and the results of
physical examination, CBC, biochemical proﬁle, urinalysis,
and ultrasonography of the adrenal glands. The dogs were
5–12 years old (median 8.4) and weighed 13.7–41.6 kg (me-
dian 26.2). Four were male (1 castrated) and 6 were female
(4 spayed), and breeds included Gordon Setter (2), Tervueren
(1), Golden Retriever (1), Standard Poodle (1), Australian
Shepherd (1), Berger Blanc Suisse (1), and 3 mixed-breed
dogs. The use of the dogs had been approved by the ethical
committee of the Kanton Zurich (no. 199/2004).
Urine Collection for Measurement of Catecholamines
and Metanephrines
In all dogs, voided urine was collected in the hospital after phys-
ical examination, blood sampling, and abdominal ultrasonography.
In 13 dogs with HAC an additional urine sample was collected by
the owner 1 week after discharge to investigate whether the stress of
veterinary manipulations affected the results. This second urine
sample was collected before initiating treatment with trilostane or
before adrenalectomy.
Urine Processing for Measurement of Catecholamines
and Metanephrines
Ten milliliters of urine was placed in a plain silicone-coated tube
containing 120mL of 20% hydrochloric acid (HCl). Urinary pH was
measured with pH indicator strips (range of pH scale 1–6) and 20%
HCl was added to ensure that urine pH was 2, as reported previ-
ously.8 Urine collected by owners was protected from light and
stored at 41C for a maximum of 48 hours according to written in-
structions. The urine container was placed on ice for transportation
to the laboratory where it was stored at 201C until analysis.
Urinary free catecholamines, comprising epinephrine and nor-
epinephrine, and fractionated metanephrines, comprising free and
conjugated metanephrine and normetanephrine, were separated
and concentrations were determined quantitatively by high pressure
liquid chromatography with electrochemical detection with com-
mercial reagents from Bio-Rada as reported previously.8,9
The concentrations of urine catecholamine and metanephrine
were correlated to the concentration of urine creatinine as reported
previously.8,9
Statistical Analysis
Data were analyzed by means of nonparametric methods by Sta-
tistical Package for the Social Science (SPSS), Software Packets for
Windows, Version 11, and GraphPad PRISM for Windows, Ver-
sion 3.0. Ranges and medians are given. The Wilcoxon signed ranks
test and the Mann-Whitney U-test were used for comparisons
within groups and between groups, respectively. Dogs with PDH
and dogs with AT were classiﬁed into 1 group, called HAC because
of the low number of dogs. Bonferoni’s correction was applied and
values of Po .05 were considered signiﬁcant.
Results
Comparison of Results in Dogs with HAC, Dogs with
PHEO, and Healthy Dogs
Dogs with HAC had signiﬁcantly higher urinary
epinephrine, norepinephrine, and normetanephrine
to creatinine ratios than healthy dogs (P 5 .001, .024,
.002), whereas metanephrine to creatinine ratios did not
differ (P 5 .101). Similar results were obtained when
measurements of dogs with PHEO were compared with
those of healthy dogs (P 5 .008; .001, .001, .922).
Comparison of results of dogs with HAC and dogs
with PHEO revealed that urinary epinephrine, norepi-
nephrine, and metanephrine to creatinine ratios did not
differ (P 5 .601, .201, .370). However, the urinary nor-
metanephrine to creatinine ratio was signiﬁcantly higher
in dogs with PHEO (P 5 .011). In 4 of the 7 dogs with
PHEO urinary normetanephrine to creatinine ratios were
higher than those of dogs with HAC. Using a cut-off ra-
tio of 4 times the highest normetanephrine to creatinine
ratio measured in controls, no overlap between dogs with
HAC and dogs with PHEO was seen (Table 1, Fig 1a–d).
Comparison of Results of Urine Collected in the
Hospital and at Home in Dogs with HAC
Norepinephrine, epinephrine, normetanephrine,
and metanephrine to creatinine ratios of urine samples
collected in the hospital and those collected at home 1
week after discharge did not differ (P 5 .124, .135, .463,
.650) (Fig 2a–d).
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Discussion
The results of this study indicate that HAC might be
associated with increased concentrations of urine cat-
echolamines and metanephrines. Approximately, 50% of
dogs with HAC had urinary epinephrine, norepineph-
rine, and normetanephrine : creatinine ratios above those
of control dogs and the difference was statistically sig-
niﬁcant. Only the urinary metanephrine to creatinine
ratio did not differ between the 2 groups of dogs. HAC
is 1 of the most common endocrine diseases of dogs and
is often associated with characteristic clinical signs, in-
cluding symmetrical alopecia, thinning of the skin, and
polyphagia. However, in some cases, less speciﬁc signs
such as polyuria/polydipsia, weakness, panting, muscle
tremors, or hypertension-associated bleeding dominate,
Table 1. Ranges and medians of urinary epinephrine, norepinephrine, metanephrine, and normetanephrine to creati-
nine ratios in healthy dogs, dogs with hyperadrenocorticism (HAC), and dogs with pheochromocytoma (PHEO).
Epinephrine :
Creatinine
Norepinephrine :
Creatinine
Metanephrine :
Creatinine
Normetanephrine :
Creatinine
Healthy dogs 1.0–8.0 (3.5) 4.0–19.0 (8.0) 46.0–255.0 (105.5) 14.0–91.0 (59.5)
Dogs with HAC 2.0–73.0 (11.5) 6.0–95.0 (15.0) 26.0–227.0 (73.0) 53.0–323.0 (117.5)
Dogs with PHEO 4.0–31.0 (8.0) 11.0–40.0 (28.0) 21.0–375.0 (102.0) 157.0–925.0 (414.0)
Healthy HAC PHEO
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Fig 1. Urinary epinephrine (a), norepinephrine (b), metanephrine (c), and normetanephrine (d) to creatinine ratios in healthy dogs (n5 10,
squares), dogs with hyperadrenocorticism (HAC, n 5 14) and dogs with pheochromocytoma (PHEO, n 5 7, triangles). In dogs with HAC,
open circles represent dogs with pituitary-dependent HAC, and closed circles represent dogs with adrenocortical tumor. All urine samples
were collected in the hospital. The most important ﬁnding was that dogs with PHEO have signiﬁcantly higher urinary normetanephrine to
creatinine ratios than dogs with HAC; see text for further details.
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and therefore various other diseases including PHEO
must be considered as differential diagnosis. Both HAC
and PHEO might be associated with an abnormal ultra-
sonographic appearance of the adrenal glands.
Unfortunately, there is no pattern of echogenicity or ar-
chitecture which would help to discriminate PHEO from
other adrenal masses such as cortisol-producing tu-
mors.12 PHEO might also be difﬁcult to differentiate
from PDH ultrasonographically, especially in cases in
which the latter is associated with macronodular hyper-
plasia.2 For this reason, our study was not limited to
dogs with ATH, but instead included dogs with PDH.
PHEO and HAC (either ATH or PDH) can occur in
the same dog.13,14 We tried to eliminate the risk that our
dogs with HAC had concurrent PHEO by documenta-
tion of clinical signs after adrenalectomy (combined with
diagnostic histological ﬁndings) or a conclusive postmor-
tem examination. In dogs with PDH in which
histological examination of the adrenal glands was not
possible, it was necessary for dogs to be re-evaluated in
the hospital at regular intervals and to be clinically well
controlled for 6 months after starting trilostane therapy.
Dogs with PHEO have signiﬁcantly increased urinary
catecholamines and normetanephrine to creatinine ratios
compared with healthy dogs.9 While urinary epinephrine
and norepinephrine to creatinine ratios overlapped to
some degree in healthy dogs and dogs with PHEO, the
urinary normetanephrine to creatinine ratio was consis-
tently higher in the latter.9 The results are in agreement
with those in humans with PHEO in which the concen-
tration of urine normetanephrine has the highest
sensitivity among the urinary variables.5,15
This ﬁnding is probably because of the fact that the
vast majority of PHEO predominantly produce norepi-
nephrine, which is metabolized into normetanephrine.
The latter is continuously released into the circulation,
whereas norepinephrine is secreted only intermittently or
in negligible amounts.5,16 According to our preliminary
results the situation might be similar in dogs. Only the
measurement of the concentration of plasma meta-
nephrines is currently thought to have a higher
sensitivity than urine normetanephrine.17
Interestingly, the urinary normetanephrine to creati-
nine ratio was also the only variable that was signiﬁ-
cantly higher in dogs with PHEO than in dogs with HAC.
In human medicine the interactions between gluco-
corticoids and catecholamines are well known.10 Gluco-
corticoids can induce catecholamine synthesis in PC12
pheochromocytoma cell cultures. They can also induce
biosynthetic enzymes, such as phenylethanolamine
N-methyltransferase, which converts norepinephrine to
epinephrine, tyrosine hydroxylase, which is the rate-
limiting enzyme in catecholamine biosynthesis, and
dopamine b-hydroxylase, which converts dopamine to
norepinephrine.10,18–20 Glucocorticoids also increase the
release of catecholamines from perfused canine adrenal
glands.21 Humans with cortisol-secreting adrenal tumors
have higher concentrations of urine catecholamines and
metanephrines than healthy controls, and levels overlap
to some extent with those of dogs with PHEO.5 To dis-
tinguish true-positive from false-positive results, the use
of cut-off values, usually 2–3 times the upper limit of
normal, is recommended.7,17 A higher cut-off value, for
example 4 times normal, is associated with a nearly 100%
probability of PHEO.22 The major remaining diagnostic
dilemma occurs in humans with smaller increases (less
than 2–3 or 4 times normal)17 because there is no reliable
way to diagnose which of these have PHEO.6
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Fig 2. Comparison of urinary epinephrine (a), norepinephrine (b), metanephrine (c), and normetanephrine (d) to creatinine ratios in samples
collected from dogs with hyperadrenocorticism (HAC) in the hospital and 1 week later at home by the owner. There was no difference between
the 2 types of urine samples with respect to any of the variables. Open circles represent dogs with PDH, and closed circles represent dogs with
adrenocortical tumor.
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The results of the present study indicate that the same
problem exists in dogs. By using a cut-off value of 4 times
the highest normetanephrine to creatinine ratio mea-
sured in healthy controls, no overlap between HAC and
PHEO was seen; all dogs with a ratio4364 had PHEO.
However, the diagnosis in 3 of the 7 dogs with PHEO
would have been missed. Using a cut-off value of 3 times
normal, 1 dog with HACwould have been misdiagnosed,
and with a cut-off value of twice normal, 4 of 13 dogs
with HAC would have been misdiagnosed as having
PHEO. In the PHEO group, the diagnosis would have
been missed in 3 resp. 2 dogs by using a cut-off value of 3
resp. 2 times normal. We currently suggest to use a cut-
off of 4 times normal, however veriﬁcation in a larger
number of cases is needed.
Veterinary care affects the concentrations of urinary
catecholamines and metanephrines.8 Thus, it would ap-
pear prudent to collect urine samples at home. This
approach has some limitations in dogs with PHEO. In
our hospital, immediate therapy with phenoxybenzamine
is usually started in dogs suspected of having PHEO.
However, phenoxybenzamine increases concentrations
of norepinephrine and normetanephrine and is a major
cause of false-positive test results in humans.17 To ensure
identical conditions in all 3 groups of dogs, urine was
sampled in the hospital after physical examination, blood
sampling, and abdominal ultrasonography and before
the administration of phenoxybenzamine. This approach
also seemed reasonable based on the ﬁnding that in dogs
with HAC the concentration of urine catecholamines and
metanephrines did not differ in urine samples collected in
the hospital and at home 1 week after discharge.
In summary, dogs with HAC had increased concen-
trations of urine catecholamines and normetanephrine.
The latter variable, however, was signiﬁcantly higher in
dogs with PHEO than in dogs with HAC. According to
our preliminary results a cut-off value of 4 times the up-
per limit of normal is associated with PHEO. However,
with this approach the diagnosis will be missed in some
dogs with PHEO. Repetitive testing and/or extensive
work-up to exclude other diseases with similar clinical
appearance might therefore be required to conﬁrm a di-
agnosis of PHEO in certain cases.
Footnote
a Bio-Rad, Munich, Germany
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